Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Freise

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|April 1, 2016
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 InhibitorAhmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Journal of Veterinary Pharmacology and Therapeutics|July 5, 2022
Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to catsTerrence P Clark, Deborah D Linton, Kevin J Freise, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.
Transfusion|January 11, 2012
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and diseaseDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Transfusion|June 22, 2010
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotinDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|April 1, 2016
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 InhibitorAhmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Journal of Veterinary Pharmacology and Therapeutics|July 5, 2022
Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to catsTerrence P Clark, Deborah D Linton, Kevin J Freise, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.
Transfusion|January 11, 2012
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and diseaseDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Transfusion|June 22, 2010
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotinDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Pageof 4